5 February 2019 - - French research and development company Valbiotis (PAR: ALVAL) (FR0013254851 ALVAL / PEA/SME eligible) has expanded its board of directors with the appointment of Murielle Cazaubiel, director of Development and Medical Affairs at Valbiotis.

Murielle has 25 years of experience in the healthcare sector.

After managing a team responsible for creating and developing clinical study management at Nantes University Hospital, in 2002, Murielle Cazaubiel founded Biofortis, a now leading CRO (Contract Research Organization).

In 2009, she successfully managed the integration of Biofortis with the Merieux group into the subsidiary Merieux Nutrisciences.

In addition, Cazaubiel took on the role of chair of the "Atlanpole Biothérapies" Cluster from 2012 to 2018, in order to develop new therapies and to accelerate the development of personalised medicine, facilitating research programs between university academics and industry professionals.

Valbiotis, which currently employs over 35 staff members, with 75% working in research and development, structured its governance to comprise a board of directors and a supervisory board.

Valbiotis is a French research and development company committed to scientific innovation for preventing and combating metabolic diseases. Its products are made for manufacturers in the agri-food and pharmaceutical industries.

Valbiotis particularly focuses on solutions to prevent type 2 diabetes, NASH (nonalcoholic steatohepatitis), obesity and cardiovascular diseases.

Valbiotis was founded in La Rochelle in early 2014 and has formed numerous partnerships with top academic centers in France and abroad, including La Rochelle University, the CNRS and Clermont Auvergne University located in Clermont-Ferrand.

These partnerships have enabled Valbiotis to benefit from strong financial leverage, particularly thanks to experts and technical partners who support its projects. The company has established three sites in France Périgny, La Rochelle and Riom and an American office in Boston.

Valbiotis is a member of the "BPI Excellence" network and received the "Innovative company" status accorded by BPI France. Valbiotis has also been awarded "Young Innovative company" status and has received major financial support from the European Union for its research programs by obtaining support from the European Regional Development Fund.